1. Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival 
Joon Ho Moon, Sang Kyun Sohn, Anna Lambie, Laura Ellis, Nada Hamad, Jieun Uhm, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, John Kuruvilla, Dennis Kim 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 4, Pages (April 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
OS according to the RSC (A) and to the subtype of cGVHD by NIH criteria (B) and GSS according to the RSC (C) and to the subtype of cGVHD by NIH criteria (D). (A) Five-year OS rate was 73.9% ± 6.0% for patients with limited cGVHD and 64.1% ± 3.3% for patients with extensive cGVHD (P = .017). (B) Five-year OS for patients with classic cGVHD (81.0% ± 3.9%) and overlap syndrome (67.7% ± 3.9%) was significantly different (P = .004). (C) Five-year GSS rate was significantly worse for patients with extensive cGVHD (73.3% ± 3.1%) than for patients with limited cGVHD (97.6% ± 1.7%, P < .001). (D) Five-year GSS rate for patients with classic cGVHD (94.5% ± 2.2%) and overlap syndrome (78.3% ± 3.5%) was significantly different (P < .001).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
OS according to NIH severity at onset (A) and at peak (B) and GSS according to NIH severity at onset (C) and at peak (D). (A) Five-year OSrate was significantly worse for severe global severity at onset: 48.5% ± 7.8% for severe versus 70.1% ± 5.0% for moderate versus 83.2% ± 3.6% for mild (P = .001). Difference between mild and moderate groups was modest (P = .064). (B) Five-year OS rate was significantly worse for severe global severity at peak: 61.5% ± 5.2% for severe versus 76.1% ± 3.9% for moderate versus 90.5% ± 5.3% for mild (P < .001). No difference was observed between mild and moderate groups (P = .151). (C) Five-year GSS rate at onset was significantly worse for patients with severe global severity (50.9% ± 7.8%) than for patients with moderate (89.7% ± 3.2%) and mild (93.5% ± 2.4%, P < .001) grades. No differences in GSS was noted between moderate and mild grades of cGVHD at onset (P = .452). (D) Five-year GSS rate at onset was significantly inferior for patients with severe global severity (69.1% ± 5.2%) than for patients with moderate (93.2% ± 2.1%) and mild (97.3% ± 2.7%, P < .001) grades. No differences in GSS were noted between moderate and mild grades of cGVHD at peak (P = .474).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
(A) Five-year CIR was significantly higher for patients with limited cGVHD (23.1% ± .2%) than for patients with extensive cGVHD (11.9% ± .1%, P = .002). (B) Five-year CIR was 17.3% ± 1.3% for classic cGVHD and 12.5% ± .7% for overlap syndrome (P = .228). (C) Five-year CIRs at onset among NIH severity groups were 11.7% ± .9% for mild, 19.3% ± 1.4% for moderate, and 9.6% ± 2.2% for severe (P = .129). (D) Five-year CIRs at peak among NIH severity groups were 11.7% ± .9% for mild, 19.3% ± 1.4% for moderate, and 9.6% ± 2.2% for severe (P = .203).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions